A detailed history of Neo Ivy Capital Management transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Neo Ivy Capital Management holds 203,048 shares of ACAD stock, worth $3.07 Million. This represents 0.65% of its overall portfolio holdings.

Number of Shares
203,048
Previous 3 6768166.67%
Holding current value
$3.07 Million
Previous $0 Infinity%
% of portfolio
0.65%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 19, 2024

BUY
$14.62 - $18.42 $2.97 Million - $3.74 Million
203,045 Added 6768166.5%
203,048 $3.3 Million
Q4 2023

Feb 23, 2024

BUY
$20.78 - $31.77 $62 - $95
3 New
3 $0
Q2 2023

Aug 15, 2023

BUY
$17.8 - $25.65 $649,397 - $935,788
36,483 New
36,483 $873,000
Q2 2022

Aug 16, 2022

SELL
$13.01 - $27.22 $16,392 - $34,297
-1,260 Reduced 79.55%
324 $4,000
Q1 2022

May 16, 2022

SELL
$20.94 - $27.5 $35,221 - $46,255
-1,682 Reduced 51.5%
1,584 $38,000
Q4 2021

Feb 15, 2022

BUY
$16.79 - $27.09 $54,836 - $88,475
3,266 New
3,266 $0
Q3 2021

Nov 16, 2021

SELL
$15.78 - $24.77 $3,976 - $6,242
-252 Closed
0 $0
Q2 2021

Aug 16, 2021

SELL
$19.4 - $27.42 $116,516 - $164,684
-6,006 Reduced 95.97%
252 $6,000
Q1 2021

Oct 07, 2021

BUY
$25.02 - $54.99 $49,514 - $108,825
1,979 Added 46.25%
6,258 $161,000
Q4 2020

Feb 16, 2021

BUY
$41.04 - $56.79 $44,569 - $61,673
1,086 Added 34.01%
4,279 $229,000
Q3 2020

Nov 17, 2020

SELL
$36.42 - $57.0 $496,732 - $777,423
-13,639 Reduced 81.03%
3,193 $131,000
Q2 2020

Aug 17, 2020

BUY
$39.26 - $52.73 $399,313 - $536,316
10,171 Added 152.69%
16,832 $0
Q1 2020

May 15, 2020

BUY
$31.65 - $46.87 $210,820 - $312,201
6,661 New
6,661 $281,000
Q3 2019

Nov 21, 2019

SELL
$22.22 - $44.01 $374,007 - $740,776
-16,832 Closed
0 $0
Q2 2019

Aug 15, 2019

BUY
$23.32 - $28.12 $335,598 - $404,674
14,391 Added 589.55%
16,832 $450,000
Q1 2019

May 15, 2019

BUY
$16.17 - $27.38 $39,470 - $66,834
2,441 New
2,441 $65,000

Others Institutions Holding ACAD

About ACADIA PHARMACEUTICALS INC


  • Ticker ACAD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 161,843,008
  • Market Cap $2.44B
  • Description
  • ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...
More about ACAD
Track This Portfolio

Track Neo Ivy Capital Management Portfolio

Follow Neo Ivy Capital Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Neo Ivy Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Neo Ivy Capital Management with notifications on news.